E. Wooltorton
Abstract
Open-access reader
Reason for posting: Rosuvastatin (Crestor) is a relatively new cholesterol-lowering drug that has become one of the top-selling new pharmaceuticals since it was first marketed in Canada in February 2003. However, Health Canada recently alerted health care professionals of reports of rhabdomyolysis
OpenAlex reports 21 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Reason for posting: Rosuvastatin (Crestor) is a relatively new cholesterol-lowering drug that has become one of the top-selling new pharmaceuticals since it was first marketed in Canada in February 2003. However, Health Canada recently alerted health care professionals of reports of rhabdomyolysis
Key concepts: Rosuvastatin, Rhabdomyolysis, Medicine, Pharmacology, Internal medicine